Value of beta-blockers in the treatment of ventricular arrhythmias

  • Nina Rehnqvist
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 110)

Abstract

Drugs with beta adrenergic blocking action are classified into Class II of the Vaughan Williams Classification. According to this, their general effect is on phase 4 on the mono action potential. The value of beta-blockers in treating arrhythmias would with this concept be mainly arrhythmias due to increased automaticity. However, the most common underlying mechanism for ventricular arrhythmias is the reentry phenomenon where phase 4 depolarisation has no meaningful contribution. In contrast to this, certain beta-blocking drugs are so far the only drugs able to generally improve prognosis when given to patients prone to sudden death. The studies where this has been documented are particularly in the postinfarction patients but also in acute ischemic heart disease a positive effect on survival has been observed. The mechanism behind this is probably that the reentry plenomenon in these patients is dependent on noradrenaline [1]. Among the beta-blockers there is also the drug sotalol which in addition to Class II action carries Class III effects. During long-term therapy metoprolol also has been shown to have this effect [2].

Keywords

Acute Myocardial Infarction Ischemic Heart Disease Ventricular Arrhythmia Ventricular Fibrillation Antiarrhythmic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wit AL, Bigger JT Jr: Electrophysiology of ventricular arrhythmias accompanying myocardial ischemia and infarction. Postgraduate Med J 1977; 53 (Suppl 1): 98–112.Google Scholar
  2. 2.
    Ahnve S: QT interval prolongation in acute myocardial infarction. Eur Heart J 1985; 6 (Suppl D): 85–95.PubMedGoogle Scholar
  3. 3.
    Lown B, Fakho AM, Hood WB et al: Coronary care unit. JAMA 1967; 199: 188.PubMedCrossRefGoogle Scholar
  4. 4.
    Olsson G, Rehnqvist N, Lundman T, Melcher A: Metoprolol treatment after acute myocardial infarction. Acta Med Scand 1981; 210: 59–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Coumel P, Rosengarten MD, Leclercq JF, Attuel P: Role of sympathetic nervous system in non-ischemic ventricular arrhythmias. Br Heart J 1982; 47: 137–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Pratt CM, Lichstein E: Ventricular antiarrhythmic effects of beta-adrenergic blocking drugs: a review of mechanism and clinical studies. J Clin Pharmacol 1982; 22: 335–47.PubMedGoogle Scholar
  7. 7.
    Lidell C, Rehnqvist N, Sjogren A, Yli-Uotila RJ, Ronnevik PK: Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study. Am Heart J 1985; 109(5): 970–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Von der Lippe G, Lund-Johansen P, Kjekshus J: Effect of timolol infarction. Acta Med Scand 1981; Suppl 651: 253–8.Google Scholar
  9. 9.
    Lichstein E, Morganroth J, Harrist R, Hubble E: Effect of propranolol on ventricular arrhythmias. The BHAT experience. Circulation 1983; 67 (Suppl I): I5–I10.PubMedGoogle Scholar
  10. 10.
    Olsson G, Rehnqvist N: Ventricular arrhythmias during the first year after acute myocardial infarction: influence of long-term treatment with metoprolol. Circulation 1984; 69 (6): 1129–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Gilson DG, Sowton E: The use of beta-adrenergic receptor blocking drugs in dysrhythmias. Prog Cardiovasc Dis 1969; XII (1): 16–39.Google Scholar
  12. 12.
    Singh BN, Jewitt DE: Beta-adrenoreceptor blocking drugs in cardiac arrhythmias. Cardiovasc Drugs 1977; 2: 119–59.Google Scholar
  13. 13.
    Muhiddin K, Nathan AW, Hellestrand KJ, Banim SO, Camm AJ: Ventricular tachycardia associated with flecainide. Lancet 1982; 2: 1219–20.Google Scholar
  14. 14.
    Campbell RWF, Murray A, Julian DG: Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Br Heart J 1981; 46: 351–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Velebit V, Podrid, Lown B, Cohen BH, Graboys TB: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982; 65 (5): 886–94.PubMedCrossRefGoogle Scholar
  16. 16.
    Rehnqvist N: Arrhythmias and their treatment in heart failure patients. Am J Cardiol 1989. In press.Google Scholar
  17. 17.
    Grayboys TB, Podrid PJ, DeSilva R: Long-term survival of patients with malignant ventricular arrhythmias treated with anti-arrhythmic drugs. Am J Cardiol 1982; 50: 437–43.CrossRefGoogle Scholar
  18. 18.
    Olsson G, Rehnqvist N: Evaluation of anti-arrhythmic effect of metoprolol treatment after acute myocardial infarction: relationship between treatment responses and survival during a 3 year follow-up. Eur Heart J 1986; 7: 312–9.PubMedGoogle Scholar
  19. 19.
    De Soyza K, Kane JJ, Murphy ML, Laddu AR, Doherty JE, Bisset JK: The long-term suppression of ventricular arrhythmia by oral acebutolol in patients with coronary artery disease. Am Heart J 1980; 100 (5): 631–8.PubMedCrossRefGoogle Scholar
  20. 20.
    McKenna WJ, Chetty S, Oakley CM, Goodwin JF: Arrhythmia in hypertrophie cardiomyopathy: Exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol 1980; 45: 1: 1–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Nademanee K, Feld G, Hendrickson J, Singh BN: Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985; 72 : 378–64.CrossRefGoogle Scholar
  22. 22.
    Schwartz PJ, Periti M, Malliani A: The long QT syndrome. Am Heart J 1975; 89 (3): 378–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Ritchie JL, Hammermeister KE, Kennedy JW: Refractory ventricular tachycardia and fibrillation in a patient with the prolapsing mitral leaflet syndrome: successful control with overdrive pacing. Am J Cardiol 1976; 37: 314–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Winkle RA, Lopes MG, Popp RL, Hancock EW: Life-threatening arrhythmias in the mitral valve prolapse syndrome. Am J Med 1976; 60: 961–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Milne JR, Camm AJ, Ward DE, Spurrell RAJ: Effect of intravenous propranolol on QT interval. A new method of assessment. Br Heart J 1980; 43: 1–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Aneglini P, Feldman MI, Lufschanowski R, Leachman RD: Cardiac arrhythmias during and after heart surgery: diagnosis and management. Prog Cardiovasc Dis 1974; XVI (5): 469–95.CrossRefGoogle Scholar
  27. 27.
    Cambell TJ, Gavaghan TP, Morgan JJ: Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. Br Heart J 1985; 54: 86–90.CrossRefGoogle Scholar
  28. 28.
    Ponten J, Biber B, Henriksson B-A, Hjalmarson A, Jonsteg C, Lundberg D: Beta-reception blockade and neurolept anaesthesia. Withdrawal vs. continuation of long-term therapy in gall-bladder and carotid artery surgery. Acta Anaesth Scand 1982; 26: 576–88.PubMedCrossRefGoogle Scholar
  29. 29.
    May GS, Eberlein KA, Furberg CD, Passami ER, DeMets DL: Secondary prevention after myocardial infarction: A review of long-term trials. Prog Cardiovasc Dis 1982; 24: 331–51.PubMedCrossRefGoogle Scholar
  30. 30.
    Rydén L, Ariniego R, Amman K, Herlitz J, Hjalmarson A, Holmberg S, Reyes C, Smedgard P, Svedberg K, Vedin A, Waagstein F, Waldenström A, Wilhelmsson C, Wedel H, Yamamoto M: A double-blind trial of metoprolol in acute myocardial infarction. Effect on ventricular tachyarrhythmias. N Engl J Med 1983; 308: 614–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Hajlmarson A: Metoprolol in acute myocardial infarction. MIAMI. Am J Cariol 1985; 56: 1G–46G.CrossRefGoogle Scholar
  32. 32.
    ISIS study group: Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS —1. Lancet 1986; 57–66.Google Scholar
  33. 33.
    Norris RM, Brown MA, Clarke ED, Barnaby PF, Georg GG, Logan RL, Sharpe DN: Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984; 2: 883–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Rehbqvist N, Olsson G, Erhardt L, Ekman A-M: Metoprolol in acute myocardial infarction reduces ventricular arrhythmias both in the early stage and after the acute event. Int. J Cardiol 1987 15: 301–8.CrossRefGoogle Scholar
  35. 35.
    Yusuf S, Petó R, Lewis J, Collins R, Sleight P: Betablockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985.Google Scholar
  36. 36.
    Champman JH, Schrank JP, Crampton RS: Idiopathic ventricular tachycardia. Am J Med 1975; 59: 470–80.CrossRefGoogle Scholar
  37. 37.
    Leahey EB, Heissenbuttel RH, Giardina E-G V, Bigger JT: Combined mexiletine and propranolol treatment refractory ventricular tachycardia. Br Med J 1980; 281: 357.PubMedCrossRefGoogle Scholar
  38. 38.
    Ikram H: Haemodynamic and electrophysiologic interactions between antiarrhythmic drugs and beta-blockers with special reference to tocainide. Am Heart J 1980; 100 (6, Part 2): 1076–80.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • Nina Rehnqvist

There are no affiliations available

Personalised recommendations